Sodium phosphate (Na3(PO4)2) | 65185-91-3

• 英文名称: Sodium phosphate (Na3(PO4)2)
• 英文别名: trisodium;dihydrogen phosphate;hydrogen phosphate
• CAS: 65185-91-3
• 化学式: H3Na3O8P2
• 分子量: 261.94
• InChiKey: LEAHFJQFYSDGGP-UHFFFAOYSA-K

计算性质

• 辛醇/水分配系数(LogP)：
  -12.74
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  164
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3,4-bis(butane-1-sulfonyl)-dihydrothiophene 、 氯化亚砜 、 Sodium phosphate (Na3(PO4)2) 在 氮 、 乙酸乙酯 、 Brine 、 Sodium sulfate-III 、 resultant crude product 、 silica gel 、 正己烷 作用下， 以 氯仿 为溶剂， 反应 36.0h， 生成 3,4-bis(butane-1-sulfonyl)thiophene
  参考文献：
  名称：

  Thiophene compound having sulfonyl group and process for producing the same

  摘要：

  一种具有磺酰基的噻吩化合物，其化学式表示为[1]。它具有高耐热性和高抗氧化性，并且可以改善在各种溶剂中的溶解性和分散性。[在该式中，R1和R2各自独立表示氢、卤素、氰等；R3和R3'各自独立表示C1-20烷基、C1-20卤代烷基、苯基（可选地由W取代）、噻吩基（可选地由W取代）等。（W表示氯等）。]

  公开号：

  US08008425B2
• 作为产物：
  描述：

  disodium;carbonate 、 磷酸 以95%的产率得到
  参考文献：
  名称：

  STAHLHEBER, N. EARL;LYON, JOHN E.

  摘要：

  DOI：

文献信息

• THIOPHENE COMPOUND HAVING SULFONYL GROUP AND PROCESS FOR PRODUCING THE SAME
  申请人：Kakiuchi Nobuyuki

  公开号：US20090127491A1

  公开（公告）日：2009-05-21

  A thiophene compound having sulfonyl groups which is represented by the formula [1]. It has high heat resistance and high unsusceptibility to oxidation and can improve solubility and dispersibility in various solvents. [In the formula, R 1 and R 2 each independently represents hydrogen, halogeno, cyano, etc.; and R 3 and R 3′ each independently represents C 1-20 alkyl, C 1-20 haloalkyl, phenyl optionally substituted by W, thienyl optionally substituted by W, etc. (W represents chlorine, etc.).]

  一种含有磺酰基的噻吩化合物，其化学式为[1]。它具有高耐热性和高抗氧化性，并可以提高在各种溶剂中的溶解度和分散性。[在公式中，R1和R2分别独立表示氢，卤素，氰基等; R3和R3'分别独立表示C1-20烷基，C1-20卤代烷基，苯基可选地取代W，噻吩基可选地取代W等（W代表氯等）。]
• Thiophene compound having phosphoric ester and process for producing the same
  申请人：Kakiuchi Nobuyuki

  公开号：US20100019229A1

  公开（公告）日：2010-01-28

  A thiophene compound having a phosphate group, for example, one represented by the formula [1]. The compound has high resistance to heat and oxidation and can be improved in solubility or dispersibility in various solvents. (In the formula, R 1 and R 2 each independently represents, e.g., hydrogen, halogeno, cyano, or phenyl optionally substituted by W; and R 3 to R 6 each independently represents —OR 7 , SR 8 , or —NR 9 2 , provided that R 7 to R 9 each independently represents hydrogen, C 1-10 alkyl, or phenyl optionally substituted by W and W represents halogeno, cyano, nitro, hydroxyl, mercapto, amino, formyl, carboxy, C 1-10 alkyl, etc.)

  一种含磷酸基的噻吩化合物，例如，由公式[1]表示的化合物。该化合物具有高耐热性和抗氧化性，并且可以在各种溶剂中改善溶解性或分散性。（在公式中，R1和R2各自独立地表示氢，卤素，氰基或苯基，可选择地被W取代；而R3到R6各自独立地表示-OR7，SR8或-NR92，前提是R7到R9各自独立地表示氢，C1-10烷基或可选择地被W取代的苯基，W表示卤素，氰基，硝基，羟基，巯基，氨基，甲酰基，羧基，C1-10烷基等。）
• Use of Icariside II in Manufacture of Products for Preventing or Treating Male or Female Sexual Dysfunction
  申请人：Xin Zhongcheng

  公开号：US20110301106A1

  公开（公告）日：2011-12-08

  The present invention provides the use of icariside II or extract comprising thereof in manufacture of products for preventing or treating male or female sexual dysfunction, in particular, the use for improving pathological or organical changes in erectile tissues of patients with erectile dysfunction.

  本发明提供了使用淫羊藿苷II或其提取物制造用于预防或治疗男性或女性性功能障碍的产品，特别是用于改善患有勃起功能障碍的患者的勃起组织的病理或器质性变化的用途。
• ANGIOTENSIN II RECEPTOR ANTAGONISTS
  申请人：Sebhat lyassu K.

  公开号：US20100152258A1

  公开（公告）日：2010-06-17

  A compound having the structure (Formula I), wherein Y is —Y 1 , —Y 2 , —Y 3 , —Y 4 , —Y 5 ; Y 1 is C(O) or C(R 1 R 2 ); Y 2 is O, C(O), P(O)(OH) or CH 2 , provided that when Y 1 is C(O), Y 2 is not C(O); R 1 is selected from the group consisting of hydrogen and C 1-4 alkyl; R 2 is selected from the pup consisting of hydrogen, C 1-4 alkyl, and —OC(O)C 1-4 alkyl; Y 3 is O, C(O) or CH 2 , provided that when Y 2 is C(O), then Y 3 is not C(O), and further provided that when Y 2 is O, then Y 3 is not O; Y 4 is O or CH 2 or is absent, provided that when Y 3 is O, then Y 4 is not O; Y5 is —(CH 2 ) 1-2 —(X) 0-1 —(CH 2 ) 0-1 — or is absent; X is —O— or —CR 3 R 4 —; and R 3 and R 4 are independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; or a pharmaceutically acceptable salt thereof, which is useful for treating hypertension.

  一种具有结构（式I）的化合物，其中Y为-Y1，-Y2，-Y3，-Y4，-Y5; Y1为C（O）或C（R1R2）; Y2为O，C（O），P（O）（OH）或CH2，前提是当Y1为C（O）时，Y2不是C（O）; R1选自氢和C1-4烷基组成的群; R2选自氢，C1-4烷基和-OC（O）C1-4烷基组成的群; Y3为O，C（O）或 ，前提是当Y2为C（O）时，Y3不是C（O），并且当Y2为O时，Y3不是O; Y4为O或 或不存在，前提是当Y3为O时，Y4不是O; Y5为-( )1-2-(X)0-1-( )0-1-或不存在; X为-O-或-CR3R4-; R3和R4独立地选自氢和C1-C4烷基组成的群; 或其药学上可接受的盐，用于治疗高血压。
• Angiotensin II receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07834042B2

  公开（公告）日：2010-11-16

  A compound having the structure (Formula I), wherein Y is —Y1—Y2—Y3—Y4—Y5—; Y1 is C(O) or C(R1R2); Y2 is O, C(O), P(O)(OH) or CH2, provided that when Y1 is C(O), Y2 is not C(O); R1 is selected from the group consisting of hydrogen and C1-4 alkyl; R2 is selected from the pup consisting of hydrogen, C1-4 alkyl, and —OC(O)C1-4 alkyl; Y3 is O, C(O) or CH2, provided that when Y2 is C(O), then Y3 is not C(O), and further provided that when Y2 is O, then Y3 is not O; Y4 is O or CH2 or is absent, provided that when Y3 is O, then Y4 is not O; Y5 is —(CH2)1-2—(X)0-1—(CH2)0-1— or is absent; X is —O— or —CR3R4—; and R3 and R4 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; or a pharmaceutically acceptable salt thereof, which is useful for treating hypertension.

  一种具有结构（式I）的化合物，其中Y为—Y1—Y2—Y3—Y4—Y5—; Y1为C（O）或C（R1R2）; Y2为O，C（O），P（O）（OH）或CH2，但当Y1为C（O）时，Y2不为C（O）; R1选自由氢和C1-4烷基组成的群; R2选自由氢，C1-4烷基和—OC（O）C1-4烷基组成的群; Y3为O，C（O）或 ，但当Y2为C（O）时，Y3不为C（O），并且当Y2为O时，Y3不为O; Y4为O或 或不存在，但当Y3为O时，Y4不为O; Y5为—（ ）1-2—（X）0-1—（ ）0-1—或不存在; X为—O—或—CR3R4—; R3和R4分别选自由氢和C1-C4烷基组成的群; 或其药学上可接受的盐，用于治疗高血压。